Mazdutide is a once-weekly injectable peptide that activates the GLP-1 receptor and the glucagon receptor together, which separates it from the single-target GLP-1 drugs most readers already know by name. The honest bottom line arrives before the data does: the human clinical evidence is real and reasonably strong within its scope, and the drug is approved in China only, with no FDA or EMA authorization anywhere else. That combination, genuine efficacy data paired with no lawful supply in most of the world, is what defines the practical situation of anyone reading about it.
Mazdutide received its first regulatory approval from China's National Medical Products Administration in 2025 for long-term weight management and remains unapproved by the United States Food and Drug Administration and the European Medicines Agency.
The molecule is a synthetic analogue of oxyntomodulin, a gut hormone released after eating that binds both the GLP-1 receptor and the glucagon receptor. Native oxyntomodulin degrades within minutes, so the peptide was re-engineered with amino acid substitutions and a fatty acid chain that anchors it to serum albumin, stretching its circulating half-life far enough to support one injection per week. The two receptor arms carry different levels of evidentiary maturity, and the glucagon arm is both the reason the drug is distinctive and the source of its particular monitoring questions.
Mazdutide is a dual GLP-1 and glucagon receptor agonist engineered from oxyntomodulin with albumin binding that supports once-weekly subcutaneous dosing.
This is human clinical evidence, not mechanism or animal data, which places it at the strongest of the three evidence levels. It rests on two named Innovent programs run in China: the GLORY series in obesity and overweight, and the DREAMS series in type 2 diabetes. GLORY-1 randomized several hundred adults to once-weekly mazdutide at four or six milligrams or placebo for forty-eight weeks, and the dose-response pattern it produced is the figure most often quoted elsewhere.
| GLORY-1 outcome (48 weeks) | Mazdutide 4 mg | Mazdutide 6 mg |
|---|---|---|
| Average weight reduction from baseline | roughly 12 percent | roughly 14 percent |
| Placebo-adjusted difference | roughly 11 points | roughly 14 points |
| Participants reaching 15 percent loss | about one third | about one half |
| Placebo arm weight change | essentially unchanged | essentially unchanged |
In the GLORY-1 trial, once-weekly mazdutide at four and six milligrams produced average weight reductions of roughly twelve to fourteen percent from baseline over forty-eight weeks in a study population of almost entirely Chinese adults whose average starting body weight was lower than in comparable North American and European obesity trials.
Gastrointestinal complaints dominate the reported safety picture, as they do for the whole incretin class, and they cluster around the dose escalation weeks rather than spreading evenly through treatment. What separates mazdutide from a pure GLP-1 agonist sits in the glucagon column: small average heart rate increases and transient liver enzyme elevations that regulators watch closely. Neither produced a pattern of serious cardiac or hepatic injury in the published data, though the follow-up window is short enough that the question stays open.
Persistent abdominal pain is the symptom the published literature identifies as warranting prompt clinical evaluation during incretin therapy, given recognized if uncommon risks of pancreatitis and gallbladder disease.
The drug was invented in one country and approved in another. Eli Lilly originated the molecule and licensed development and commercialization rights in China to Innovent Biologics, which ran the pivotal trials and filed there. Approval in one jurisdiction confers nothing in another, and the gap between demand and lawful availability is precisely the space where grey-market supply appears.
A research-use-only label is an accurate description of a product manufactured outside pharmaceutical oversight and never intended for injection into a person, not a legal technicality or a workaround.
Nobody in the trial programs started at a maintenance dose. The published protocols describe a stepwise escalation, and the reason is measurable rather than procedural: the gastrointestinal effects that drive most discontinuations concentrate in the weeks immediately following each dose increase, so a slower ramp improves the odds a participant remains on treatment long enough to see benefit.
Product labeling describes pens as refrigerated until first use and then held at room temperature for a limited period, with a frozen pen discarded rather than used.
The cleanest separation between these three is what each one binds. Semaglutide targets the GLP-1 receptor alone, tirzepatide adds GIP, and mazdutide adds the glucagon receptor, a genuinely different second target working through energy expenditure and hepatic fat mobilization rather than a second incretin pathway. Lining the headline percentages up in a row is tempting and mostly misleading, because no head-to-head trial exists and the programs differ in duration, dose ceiling, and above all in population.
| Criterion | Semaglutide | Tirzepatide | Mazdutide |
|---|---|---|---|
| Receptor targets | GLP-1 | GLP-1 + GIP | GLP-1 + glucagon |
| Pivotal trial weight loss | roughly 15 percent | roughly 20 to 22 percent | roughly 12 to 14 percent |
| Trial duration | 68 weeks | 72 weeks | 48 weeks |
| Approval footprint | US, EU, and widely | US, EU, and widely | China only |
No head-to-head trial has compared mazdutide with semaglutide or tirzepatide, so every efficacy comparison between them is indirect and confounded by differing trial duration, dose ceilings, and starting body weight across populations.
Eligibility in the approved market follows the standard obesity pharmacotherapy pattern, adjusted to Asian body composition thresholds. The criteria sit lower in absolute body mass index terms than American thresholds because metabolic risk rises at a lower body mass index in East Asian populations, a genuine clinical distinction rather than a regulatory quirk. Several histories exclude a person outright, and the liver-related ones carry extra weight here because of the glucagon component.
Because meaningful weight loss can restore fertility unexpectedly, the published guidance for this class places a contraception discussion before treatment initiation rather than after.
Pricing information comes almost entirely from the Chinese market, where the drug launched at a monthly cost meaningfully below what branded GLP-1 medicines command in the United States. The more useful financial frame is not the monthly figure but the arithmetic of a chronic condition: trial evidence across the class shows weight returning when the drug stops, which converts any monthly price into an ongoing commitment measured in years. That arithmetic drives more discontinuations than side effects do.
Obesity pharmacotherapy across this class carries no defined end date, and the documented pattern of weight regain after discontinuation converts the monthly price into a multi-year commitment rather than a finite course of treatment.
The most important long-term fact about this class is also the least popular one. Withdrawal studies of GLP-1 receptor agonists have consistently shown participants recovering the majority of lost weight within roughly a year of discontinuation, with blood pressure and metabolic improvements drifting back toward baseline alongside it. No mazdutide-specific off-treatment follow-up has been published, so nothing more precise can honestly be said about this molecule in particular.
Withdrawal studies across GLP-1 receptor agonists report that the majority of lost weight returns within roughly a year of stopping, which is why obesity medicine increasingly frames this class as ongoing management of a chronic condition rather than a finite intervention.
Educational use only. This article describes what the published scientific and clinical literature reports about Mazdutide. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
